Visit our website
New America Cypbersecurity Initiative
New America Cypbersecurity Initiative
MIT Technology Review
MIT Technology Review
io9
io9
Techdirt
Techdirt
Knowledge@Wharton
Knowledge@Wharton
Bioscience Technology
Bioscience Technology
redOrbit
redOrbit
Technology & Marketing Law Blog
Technology & Marketing Law Blog
Popular Science Blog
Popular Science Blog
Pew Research Center
Pew Research Center
Genomics Law Report
Genomics Law Report
Science 2.0
Science 2.0
The Guardian Headquarters
The Guardian Headquarters
Genetic Literacy Project
Genetic Literacy Project
Disclaimer

Statements posted on this blog represent the views of individual authors and do not necessarily represent the views of the Center for Law Science & Innovation (which does not take positions on policy issues) or of the Sandra Day O'Connor College of Law or Arizona State University.

Wednesday Web Watch for March 11, 2015

WWW4

The risk, benefit and cost analysis generated by gene therapy is highlighted this week in an article by Meredith Knight, entitled Gene therapy dilemma: Would you tweak your child’s genes if it might prolong life but leave her deaf?  Writing for Genetic Literacy Project, Knight discusses the various issues that come into play with the likely upcoming surge of gene therapy treatments.  As she points out, the players are not just the afflicted individual and his or her family but also governments, drug developers, healthcare providers and insurance companies.